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Abstract
Enhanced ceramide glycosylation catalyzed by glucosylceramide synthase (GCS) limits therapeutic efficiencies of
antineoplastic agents including doxorubicin in drug-resistant cancer cells. Aimed to determine the role of GCS in tumor
response to chemotherapy, a new mixed-backbone oligonucleotide (MBO-asGCS) with higher stability and efficiency has
been generated to silence human GCS gene. MBO-asGCS was taken up efficiently in both drug-sensitive and drug-resistant
cells, but it selectively suppressed GCS overexpression, and sensitized drug-resistant cells. MBO-asGCS increased
doxorubicin sensitivity by 83-fold in human NCI/ADR-RES, and 43-fold in murine EMT6/AR1 breast cancer cells, respectively.
In tumor-bearing mice, MBO-asGCS treatment dramatically inhibited the growth of multidrug-resistant NCI/ADR-RE tumors,
decreasing tumor volume to 37%, as compared with scrambled control. Furthermore, MBO-asGCS sensitized multidrug-
resistant tumors to chemotherapy, increasing doxorubicin efficiency greater than 2-fold. The sensitization effects of MBO-
asGCS relied on the decreases of gene expression and enzyme activity of GCS, and on the increases of C18-ceramide and of
caspase-executed apoptosis. MBO-asGCS was accumulation in tumor xenografts was greater in other tissues, excepting liver
and kidneys; but MBO-asGCS did not exert significant toxic effects on liver and kidneys. This study, for the first time in vivo,
has demonstrated that GCS is a promising therapeutic target for cancer drug resistance, and MBO-asGCS has the potential
to be developed as an antineoplastic agent.
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Introduction
Chemotherapy remains a standard treatment for patients with
metastatic cancers. However, multidrug resistance (MDR) often
occurs in more than 50% of patients with cancers during the
course of chemotherapy, ultimately resulting in treatment failures
[1,2]. Overexpression of genes that modulate drug action, cell
proliferation and apoptosis is the cornerstone for MDR. Recent
studies indicated that glucosylceramide synthase (GCS) is a gene
for drug resistance in cancer cells [3–6]. GCS enzyme converts
ceramide to glucosylceramide, thereby deactivating ceramide [7].
Ceramide, a lipid second messenger, mediates growth arrest and
apoptosis of cells; ceramide-induced apoptosis contributes to the
therapeutic efficiencies of anthracyclines, taxanes, Vinca alkaloids,
cytokines, and irradiation [4,8–10]. Transfection of GCS gene
confers cellular resistance to doxorubicin, tumor necrosis factor-a
and daunorubicin in various cancer cell lines [11–13]. GCS
overexpression has been identified in MDR cell lines of breast,
ovarian, cervical, and colorectal cancers [14,15]. GCS has been
found overexpressed in leukemia patients with poor-response to
chemotherapy [16,17] and GCS overexpression is associated with
the prognosis of breast cancer [18]. Furthermore, a number of
studies over past decade have demonstrated that inhibition of GCS
sensitizes MDR cells to anticancer drugs [3,15,19–26]. Suppress-
ing GCS overexpression using small interfering RNA (siRNA),
phosphorothioate antisense oligonucleotide (PS-oligo) and trans-
fection of antisense sequence overcomes MDR in human breast,
colon, cervical and ovarian cancer cell lines [3,15,20,23,24,26].
Inhibition of GCS enzyme with small molecules, such as D-threo-1-
phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), sen-
sitizes cancer cells to doxorubicin, paclitaxel and vincristine
[19,21,22,25].
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newly identified mechanism promoting cellular resistance; how-
ever, whether GCS directly modulates tumor response to
chemotherapy remains to be clarified. Effectively silencing the
GCS gene in vivo can determine whether GCS has a role in tumor
drug resistance. Mixed-backbone oligonucleotide (MBO), one type
of second-generation antisense oligonucleotides, can specifically
inhibit the expression of pathogenic genes and has a better safety
profile than PS-oligo in vivo [27,28]. Using the strategy of gene
silencing with MBO, we examined the role of GCS in cancer drug
resistance.
Materials and Methods
Reagents and cell lines
A mixed-backbone oligonucleotide (MBO) was designed to target
the open reading frame (ORF) 18–37 of human GCS [23,29] and
designated as MBO-asGCS. A scrambled control (MBO-SC) had
the same chemical components as MBO-asGCS, but no sequence
specificity. MBOs were 20-mer phosphorothioate DNA, excepting
four bases at either the 59 end or the 39 end was replaced by 29-O-
methyl RNA. MBOs and Cy3-labeled MBO-asGCS were synthe-
sized,andpurifiedbyreverse-phaseHPLCand desalting(Integrated
DNA Technologies, Inc., Coralville, IA). Lipofectamine
TM 2000,
Opti-MEM I, and NBD C6-ceramide (N-hexanoyl-D-erythro-
sphingosine) complexed to BSA were purchased from Invitrogen
(Carlsbad, CA). Doxorubicin hydrochloride was purchased from
Sigma. Anti-human GCS rabbit serum (GCS 6.2) [30] was kindly
provided by Drs. D. L. Marks and R. E. Pagano (Mayo Clinic
and Foundation, Rochester, MN). Anti-GCS goat IgG was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and
anti-active caspase-7 rabbit IgG was from Calbiochem (La Jolla,
CA). C6-Ceramide (N-hexanoyl-D-erythro-sphingosine) and NBD
C6-glucosylceramide were purchased from Matreya (Pleasant
Gap, PA).
Human breast adenocarcinoma cell line MCF-7 and drug-
resistant NCI/ADR-RE (previously designed as MCF-7-AdrR)
[31,32] were kindly provided by Dr. Kenneth Cowan (UNMC
Eppley Cancer Center, Omaha, NE) and Dr. Merrill Goldsmith
(National Cancer Institute, Bethesda, MD). Murine breast carcino-
ma cell line EMT6 and its drug-resistant counterpart EMT6/AR1
[33,34] were kindly provided by Dr. Ian Tannock (Ontario Cancer
Institute, Toronto, ON, Canada). MCF-7 and NCI/ADR-RE cells
were maintained in RPMI-1640 medium, and EMT6 and EMT6/
AR1 cells were maintained in Dulbecco’s modified eagle medium
(DMEM). Both media were supplied with 10% fetus bovine serum
(FBS), 100 units/ml penicillin, 100 mg/ml streptomycin, and
584 mg/liter L-glutamine. Cells were cultured in an incubator
humidified with 95% air and 5% CO2 at 37uC. EMT6/AR1 cells
were cultured in medium containing 1 mg/ml of doxorubicin for 2
days/week in addition to the above components.
MBO uptake
Cy3-labeled MBO-asGCS was used to analyze MBO uptake, as
described previously with modification [35]. Briefly, cells
(5610
4 cells/well) were seeded in 24-well plates and cultured in
10% FBS RPMI-1640 medium. After 24 hr growth, cells were
exposed to 50 nM Cy3-MBO-asGCS with Lipofectamine
TM 2000
in Opti-MEM I reduced-serum medium for defined periods. After
washing with ice-cold PBS three times and addition of methanol
(200 ml/well), cellular fluorescence was measured at lexcitation
550 nm/lemission 570 nm using a Synergy HT multi-detection
microplate reader (BioTek, Winnooski, VT). MBO-asGCS uptake
was normalized by cell numbers and represented by the
percentage of cellular fluorescence of total fluorescence added in
the medium before incubation. To characterize the in vivo uptake
of MBO-asGCS, Cy3-MBO-asGCS was administrated by intra-
peritoneal injection (1,4 mg/kg) into tumor-bearing mice.
Tissues were collected 7 hr after injection, and the fluorescence
in tissue homogenates was measured in the same manner as
described for cells.
Cell viability assay
Cell viability was analyzed by quantitation of ATP, an indicator
of active cells, using the CellTiter-Glo luminescent cell viability
assay (Promega, Madison, WI), as described previously [15].
Briefly, cells (4,000 cells/well) were grown in 96-well plates with
10% FBS RPMI-1640 medium for 24 hr. MBOs were introduced
into cells by Lipofectamine 2000 (vehicle control) in Opti-MEM I
reduced-serum medium, for a 4 hr incubation. Cells were then
incubated with increasing concentrations of agents in 5% FBS
medium for additional 72 hr. Cell viability was determined by the
measurement of luminescent ATP in a Synergy HT microplate
reader, following incubation with CellTiter-Glo reagent.
Tumor xenografts and treatments
All animals were handled in strict accordance with good animal
practice as defined by AAALAC, and all animal work was
approved by the IACUC, University of Louisiana at Monroe
(ULM). A drug-resistant tumor model was established with the
protocols described previously [36,37]. Athymic nude mice
(Foxn1
nu/Foxn1
+, 4–5 weeks, female) were purchased from Harlan
(Indianapolis, IN) and maintained in the ULM vivarium. Cells of
NCI/ADR-RE (3–5 passages) were washed with and resuspended
in serum-free RPMI-1640 medium. Cell suspensions (1610
6 cells
in 20 ml per mouse) were injected into the second left mammary
gland, just beneath the nipple. Mice were monitored by measuring
tumor growth, body weight and clinical observation. Once tumors
reached ,2 mm in diameter, mice were randomly divided into
treatment and control groups (ten mice per group). MBO-asGCS
or MBO-SC, dissolved in RPMI 1640 medium was injected at a
dose of 1 mg/kg, twice per week, at the tumor site. The control
group received medium only (saline). Doxorubicin was adminis-
tered by intraperitoneal injection, at 2 mg/kg once a week. In
combinations, doxorubicin was administered with medium (saline)
or MBOs, respectively.
RNA extraction and GCS mRNA analysis
Cellular RNA was extracted and purified using a SV total RNA
isolation kit (Promega). Equal amounts of RNA (100 ng) were used
for RT-PCR and a 441-bp GCS fragment was produced using a
SuperScript
TM One-step RT-PCR with Platinum Taq kit (Invitro-
gen), as described previously [13,15]. The levels of GCS mRNA
were semi-quantitated by optical densitometry and normalized
using the OD values of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). For quantitative RT-PCR, cDNA was synthesized using
the SuperScript
TM First-Strand synthesis system and random
hexamer reverse transcription primers (Invitrogen). Under up-
stream primer (59-GACCTGGCCTTGGAGGGAAT-39)a n d
downstream primer (59-GAGACACCTGGGAGCTTGCT-39)
conditions, a 149-bp fragment in the region of GCS gene (303 to
451) was produced using a QuantiFast SYBR Green PCR kit
(Qiagen, Valencia, CA) with a MyiQ real-time PCR detection
system (Bio-RAD Laboratories, Hercules, CA), as described
previously [15]. Endogenous GAPDH (200 bp; upstream primer
59-ATGGGGAAGGTGAAGGTCGG-39; downstream primer 59-
TCCACCACCCTGTTGCTGTA-39) was used for normalization.
Quantitation was carried out using human GCS DNA standard
GCS and Cancer Drug Resistance
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[3,20].
Western blot analysis
After treatments, cells or tissue homogenates were lysed using
NP40 cell lysis buffer (Biosource, Camarillo, CA). Equal amount
of proteins (50 mg/lane) were resolved using 4–20% gradient
SDS-PAGE (Invitrogen). The transferred blots were blocked with
5% fat-free milk PBS and immuno-blotted with primary
antibodies (anti-GCS goat IgG or anti-active caspase-7 rabbit
IgG) at 1:500 dilution, at 4uC for overnight, as described
previously [3,13,15]. The antigen-antibody in blots was detected
by using a second antibody-conjugated horseradish peroxidase
(HRP) and enzyme-linked chemiluminescence (ECL) plus sub-
strate (GE Healthcare, Piscataway, NJ). Endogenous GAPDH
was used as a loading control. The levels of GCS protein were
represented by the ratios of optical densities in GCS bands
normalized against GAPDH.
Figure 1. Mixed-backbone oligonucleotide targeting human glucosylceramide synthase. a. Cellular uptake of MBO. After exposure of
cancer cells to Cy3-labeled MBO-asGCS (50 nM) for the indicated periods, cellular Cy3-MBO-asGCS was measured at lexcitation 550 nm and lemission
570 nm. b. Influence of MBOs on GCS expression. MBO-asGCS or MBO-SC was introduced into NCI/ADR-RE cells (ADR-RE) with Lipofectamine 2000 in
Opti-EME I reduced-serum medium. After 48 hr growth, total RNA and protein were extracted. Total RNA (100 ng/reaction) was analyzed by RT-PCR.
For Western blots, total protein (50 mg/lane) was subjected to 4–20% SDS-PAGE electrophoresis. Proteins were transferred to nitrocellulose and
immunoblotted with GCS primary antibody (1:500) and detected using ECL plus. GCS protein levels were presented as the ratios of the optical
densities in GCS bands normalized against GAPDH.
doi:10.1371/journal.pone.0006938.g001
Figure 2. MBO-asGCS suppresses GCS expression in drug-resistant cancer cells. Drug-resistant and drug-sensitive cell lines (NCI/ADR-RE,
MCF-7; EMT6/AR1, EMT6) were treated with MBO-asGCS (50 nM) for 48 hr. a. Quantitative RT-PCR. Isolated total RNA (100 ng/reaction) was
synthesized to cDNA and analyzed by quantitative real-time PCR. b. Western blot. Total protein (50 mg/lane) was subjected to Western blot analysis;
GCS expression levels are presented as the density ratio of GCS/GAPDH bands. c. Cellular ceramide glycosylation. After 24 hr MBO transfection, cells
were incubated 500 mM NBD C6-ceramide complexed to BSA. After 2 hr incubation, cellular sphingolipids were extracted and resolved by high-
performance thin-layer chromatography and quantitated. ADR-RE, NCI/ADR-RE; *, p,0.001 compared with drug-sensitive cells; **, p,0.001
compared with corresponding vehicle control.
doi:10.1371/journal.pone.0006938.g002
GCS and Cancer Drug Resistance
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Tumors were removed, fixed and maintained in paraffin blocks.
Microsections of tumors (5 mm) were stained in H&E and identified
by pathologists (Dr. Bao, J., Pathology, Louisiana State University
Health Sciences Center). For immunostaining, antigens were
retrieved in steaming sodium citrate buffer (10 mM, 0.05%
Tween-20, pH 6.0; for 10 min). After blocking in 2% block solution
(Vector Laboratories, Burlingame, CA), the slides were incubated
with anti-GCS rabbit serum (1:100) overnight at 4uC. Antibody-
bound cells on slides were recognized by Alexa Fluor
H488 goat anti-
rabbit IgG (Invitrogen). Cell nuclei were counterstained with 49,6 -
diamidino-2-phenylindole (DAPI) in mounting solution (Vector
Laboratories). The slides were observed using a Nikon TE-2000
phase contrast microscope, and the images were captured by a
Retiga 2300
TM monochrome digital camera using IPLab
TM image
analysis program (Scanalytics Inc., Rockville, MD).
Cellular ceramide glycosylation assay
Cells (1610
6 cells/dish) were grown 24 hr in 35-mm dishes with
10% FBS RPMI-1640 medium, and MBO-asGCS (50 nM) was then
introduced as described above. After 12 hr of growth in 10% RPMI-
1640 medium, cells were switched to 1% bovine serum albumin (fatty
acid free)mediumcontaining 500 mMNB DC 6-ceramide complexed
to BSA (Invitrogen). After a 2 hr incubation at 37uC, lipids were
extracted, and resolved by partisil high-performance TLC plates with
fluorescent indicator with solvent of chloroform/methanol/3.5 N
ammonium hydroxide (85:15:1), as described previously [15]. NBD
C6-glucosylceramide and NBD C6-ceramide were identified using an
AlphaImager HP imaging system (Alpha Innotech, San Leandro,
CA), and quantitated with a Synergy HT multi-detection microplate
reader (BioTek). For quantitation, calibration curves were established
after TLC separation of NBD C6-ceramide and NBD C6-
glucosylceramide.
High performance LC/MS ceramide measurement
The levels of endogenous ceramides in tumors were measured
using normal phase high performance liquid chromatography
coupled to atmospheric pressure chemical ionization-mass spec-
trometry (LC/MS) as described previously [38,39]. After MBO
treatment (1 mg/kg, twice per week for 38 days), doxorubicin
was given by intraperitoneal injection at 2 mg/kg, and tumor
tissues collected at the indicated periods after doxorubicin
administration. The ceramide levels were normalized against
phosphorus in tissues.
Figure 3. MBO-asGCS increases doxorubicin sensitivity in drug-resistant cancer cells. Cells (4,000/well) were plated in 96-well plates and
pretreated with MBO-asGCS (50 nM). After 24 hr growth, cells were shifted to 5% FBS medium containing increasing concentrations of agents and
grown for additional 72 hr. Cell viability was measured using the CellTiter-Glo luminescent cell viability assay. a. Cell viability after C6-ceramide
treatment. ADR-RE, NCI/ADR-RE cells; *, p,0.01 compared with vehicle treatment. b. EC50 values for C6-ceramide. *, p,0.001 compared with vehicle
treatments. c. Cell viability after doxorubicin treatment. d. EC50 values for doxorubicin. *, p,0.001 compared with vehicle treatment.
doi:10.1371/journal.pone.0006938.g003
GCS and Cancer Drug Resistance
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Caspase-3/7 activity was assayed by DEVD-aminoluciferin
cleavage, using the caspase-Glo
H 3/7 assay kit (Promega), following
the manufacturer’s instruction. Briefly, NCI/ADR-RE cells were
cultured in 100-mm dishes (5610
5 cells per dish) with 10% FBS
RPMI medium. After 24 hr of growth, MBO-asGCS was
introduced into cells with Lipofectamine 2000 in Opti-MEM I
reduced-serum medium. Cells were incubated for a 48 hr in 5%
FBS medium containing 5 mM doxorubicin. After harvest, cell
lysates were incubated with proluminescent DEVD-aminoluciferin
and thermostable luciferase. The luminescence for each sample was
measured using a Synergy HP multiplate reader and normalized by
proteins. For in-vivo studies, tissue homogenates (25 mg/100 ml)
from each group were immediately used for caspase-3/7 assay.
Figure 4. MBO-asGCS enhances doxorubicin-induced apoptosis. NCI/ADR-RE cells were pretreated with MBO-asGCS (0–300 nM) and then
exposed to doxorubicin (Dox. 5 mM) for 48 hr. a. Caspase-3/7 assay. RLU, relative luminescence units; *, p,0.005 compared with cells exposed to
doxorubicin alone. b. Flow cytometry analysis. Apoptosis was quantitated by flow cytometry following propidium iodide staining (right panel). Left-
hand bar graph is based on apoptotic cells detected on the sub-G0 phase. *, p,0.001 compared with cells exposed to doxorubicin alone. c. TUNEL
staining for apoptosis. After pretreatment of MBO-asGCS or MBO-SC (50 nM), NCI/ADR-RE cells were exposed to doxorubicin (5 mM) for 48 hr.
Apoptotic cells (TUNEL
+) exhibit green fluorescence (x 200).
doi:10.1371/journal.pone.0006938.g004
GCS and Cancer Drug Resistance
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The analyses were performed using propidium iodide (PI)
staining with subsequent FACS analysis, as described previously
[40] with minimal modification. Cells (5610
5 per dish) were
cultured in 100-mm dishes with 10% FBS RPMI 1640 medium for
24 hr. MBO-asGCS was then introduced into cells with
Lipofectamine 2000 in Opti-MEM I reduced-serum medium.
Cells were incubated in 5% FBS medium in the presence of 5 mM
doxorubicin for additional 48 hr. After harvest with trypsinization
and centrifugation, cell pellets were resuspended and exposed to
0.01% PI in staining solution (0.1% sodium citrate, 0.3% Triton
X-100, 2 mg/ml ribonuclease A) at 4uC for 30 min, followed by
flow cytometry analysis using FACSCalibur (BD Biosciences, San
Jose, CA). Sub-phase G1/G0 was defined as indicative of
apoptotic cells; 10,000 events were counted.
Apoptotic cell death detection using terminal-
deoxynucleotide-transferase-mediated dUTP nick end
labeling (TUNEL) staining
Apoptotic cells were detected by measurement of nuclear DNA
fragmentation using the DeadEnd fluorometric TUNEL system
(Promega), following the manufacturer’s instruction, as described
previously [13,23]. Briefly, cells (2610
4 per chamber) were
cultured in 4-chamber slides with 10% FBS RPMI 1640 medium.
MBOs were introduced into cells with Lipofectamine 2000 in
Opti-MEM I reduced-serum medium (4 hr incubation). Cells were
then incubated in 5% FBS medium in the presence of 5 mM
doxorubicin for additional 48 hr. Cells were fixed with methanol
digested for 20 min with 0.2 mg/ml proteinase K in 10 mM Tris-
HCl, pH 8.0, and labeled for 90 min with fluorescein-12-dUTP
terminal deoxynucleotide transferase reaction mixture at 37uCi na
humidified chamber. After mounting with DAPI, slides were
observed using a Nikon TE-2000 phase contrast microscope with
digital image capture.
All experiments in cells were performed in triplicate and repeated
at least two times. Data were analyzed by using Microsoft Excel
2003 and Prism (V.4) and presented as mean6SD. Tumor volume
(V) was calculated by V=L6W
2/2, where L was the length and W
was the width of tumors. Statistically significant differences between
samples were analyzed using two-tailed Student’s t tests for paired
and unpaired samples, p,0.05 was considered significant.
Results
MBO-asGCS suppresses GCS overexpression and
sensitizes drug-resistant cancer cells
MBO-asGCS has been designed to target the exon-1 of human
GCS gene [23,29]. The influence of MBO-asGCS and MBO-SC
(scramble control) have been examined in NCI/ADR-RE cells,
which overexpress GCS and display MDR [3,31,32]. We found
that resistant NCI/ADR-RE cells took up approximately the same
amount, 20% of total Cy3-MBO-asGCS, as drug-sensitive MCF-7
cells (Fig. 1a) in 4 hr of transfection. Similar uptake for MBO-
asGCS also has been found in drug-resistant EMT6/AR1 and
Figure 5. MBO-asGCS suppresses tumor growth in athymic nude mice. Athymic nude mice (Foxn1
nu/Foxn1
+, 10 per group) bearing drug-
resistant tumors (NCI/ADR-RE cells) were treated with either MBOs (1 mg/kg every 3 days, intratumoral injection) alone or MBOs combined with
doxorubicin (Dox, 2 mg/kg once a week, intraperitoneal injection) for 38 days. Treatments were started once tumors were visible (2 mm diameter,
day 0). a. Tumor growth. *, p,0.001 compared with treatments in the presence of saline or MBO-SC. **, p,0.001 compared with treatments in the
presence of doxorubicin or doxorubicin combined with MBO-SC. b. Body weight of mice after treatments. c. Tumors after treatments. Tumors were
photographed when mice were sacrificed at the end of treatment regimens.
doi:10.1371/journal.pone.0006938.g005
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20.3% in 4 hr). As shown in Fig. 1b, MBO-asGCS, not MBO-SC,
decreased GCS gene expression as measured by mRNA and
protein levels, in a dose-dependent manner. At low concentration
(50 nM), MBO-asGCS decreased the GCS expression to 40% of
the levels resulting with MBO-SC treatment.
We examined the effects of MBO-asGCS on GCS in drug-
resistant and drug-sensitive cancer cell lines. MDR murine
EMT6/AR1 breast cancer cells [34], like NCI/ADR-RE, over-
expressed GCS mRNA and protein (Fig. 2a, 2b). Consistent with
increases of mRNA levels and enzyme activities (Fig. 2c), GCS
protein levels in NCI/ADR-RE and EMT6/AR1 were 4-fold (2.3
vs. 0.58 ratio of GCS/GAPDH) and 10-fold (3.1 vs. 0.31) greater
than in sensitive MCF-7 and EMT6 cells, respectively. MBO-
asGCS treatment (50 nM) significantly decreased ceramide
glycosylation following a substantial decrease of GCS expression
in resistant NCI/ADR-RE and EMT6/AR1 cells. The levels of
GCS protein as well as mRNA were decreased to approximately
13% in NCI/ADR-RE (0.31 vs. 2.3) and 8% in EMT6/AR1 cells
(0.25 vs. 3.1); cellular GCS activities (as assessed by GC/Cer ratios)
were reduced to approximately 65% and 54% in NCI/ADR-RE
and EMT6/AR1, respectively (Fig. 2c). However, MBO-asGCS
did not significantly affect GCS expression in drug-sensitive MCF-
7 and EMT6 cells (Fig. 2). Given that drug-resistant and drug-
sensitive cells can take up the same amount of MBO-asGCS
(Fig. 1a), these data indicate that MBO-asGCS selectively suppress
GCS overexpression in drug-resistant cells.
Additional studies showed that MBO-asGCS significantly increased
cytotoxicity of ceramide and doxorubicin in drug-resistant cells, but
not in drug-sensitive cells. MBO-asGCSpretreatment (50 nM) did not
increase ceramide cytotoxicity in drug-sensitive MCF-7 and EMT6
cells. In contrast, MBO-asGCS (50 nM) significantly increased
ceramide cytotoxicity in drug-resistant NCI/ADR-RE and EMT6/
AR1; the EC50 values for C6-ceramide decreased to approximately
50% in both resistant cell lines (Fig. 3a, 3b). MBO-asGCS
pretreatment markedly increased doxorubicin sensitivity in drug-
resistant cells; the EC50 values for doxorubicin decreased by 83-fold
(0.18 vs. 12.5 mM) in NCI/ADR-RE, and by 43-fold (0.20 vs. 8.6 mM)
in EMT6/AR1, respectively (Fig. 3c and 3d). By comparison, MBO-
asGCS only mildly (by 50%) decreased the EC50 values for
doxorubicin in sensitive counterparts of MCF-7 and EMT6 cells.
These results demonstrate that suppressing GCS overexpression
sensitizes resistant cancer cells to therapeutic agents, such as
doxorubicin whose therapeutic efficiency is associated with ceramide
actuation [11,41,42].
MBO-asGCS promotes MDR cells to induced-apoptosis
The apoptotic impacts of anthracyclines and taxanes depend, at
least in part, on ceramide generation [3,43–45]. We assessed the
effects of MBO-asGCS treatment on ceramide-induced apoptosis
in MDR cells exposed to doxorubicin. It was found that
doxorubicin exposure induced apoptosis only in MDR cells
pretreated with MBO-asGCS. Doxorubicin increased caspase 3/
7 activity, in a dose-dependent manner, in NCI/ADR-RE cells
pretreated with MBO-asGCS (Fig. 4a). Correspondingly, flow
cytometry detected large proportions of apoptotic cells in drug-
resistant NCI/ADR-RE cells pretreated with MBO-asGCS and
then with doxorubicin, but not in cells treated with doxorubicin
alone (Fig. 4b). MBO-asGCS pretreatment increased the number
of apoptotic cells to 225% (14.7 vs. 6.5% of total of cells) and 533%
(34.9 vs. 6.5% of total cells), at 150 nM and 300 nM, respectively,
as compared with doxorubicin treatment alone. Furthermore, in
TUNEL assays, combined pretreatment of MBO-asGCS follow-
ing with doxorubicin increased the apoptotic fraction by 6-fold
(30% vs. 5% of total cells), as compared with treatments of
doxorubicin alone or doxorubicin following MBO-SC pretreat-
ment (Fig. 4C). Given that MBO-asGCS suppressed ceramide
glycosylation of GCS (Fig. 2) increasing cellular ceramide, these
data indicate that MBO-asGCS promotes MDR cancer cells to
apoptosis through ceramide-activated caspases.
MBO-asGCS sensitizes MDR tumors to doxorubicin
In order to validate whether MDR tumors rely on ceramide
glycosylation for evading toxicity, we assessed the effects of MBO-
asGCS on tumor growth and tumor response to chemotherapy in
nude mice. Treatment was started when MDR tumors became
visible (,2 mm in diameter), approximately two weeks after
inoculation of NCI/ADR-RE cells (10
6 cells/mouse). After 13
administrations of MBO (1 mg/kg, intratumoral injection, every
Figure6. MBO-asGCSsuppresses GCS expressionin tumors. Mice
bearing NCI/ADR-RE tumors were treated with MBOs alone (1 mg/kg per
3 days, intratumoral injection) or in combination with doxorubicin (Dox,
2 mg/kg per week, intraperitoneal injection) for 38 days. Total RNA and
proteins were immediately extracted from tumor homogenates. a.
Quantitative RT-PCR for GCS. GCS mRNA levels were quantitated by
using GCS standard and normalized against GAPDH. *, p.0.001
compared with saline or MBO-SC groups. b. Western blotting for GCS.
Detergent-soluble protein (50 mg/lane) extracted from tumors (three per
group) was incubated with anti-GCS or anti-GAPDH antibodies, following
PAGE and transferring. c. Immunofluorescence microscopy. Tumor
sections were stained with anti-GCS antibody (green). The nuclei were
visualized by staining with DAPI (blue, x 200).
doi:10.1371/journal.pone.0006938.g006
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not MBO-SC treatment, significantly attenuated tumor growth to
37% (336649 vs. 913658 mm
3,p ,0.01) (Fig. 5a). On contrary,
MBO-SC could not significantly affect tumor growth (783678. vs.
914658 mm
3) (Fig. 5a). Furthermore, it was found that MBO-
asGCS treatment sensitized MDR tumors to doxorubicin.
Combined treatment of MBO-asGCS with doxorubicin decreased
tumor volume to 45% (187650 vs. 411690 mm
3,p ,0.01), as
compared with the treatment of doxorubicin or doxorubicin
combined with MBO-SC (411690 mm
3; 4286100 mm
3). More-
over, these treatments did not significantly affect the body weight
of these mice. After 39 days of treatment, the mean of body weight
was 22.061.0 g in the group of MBO-asGCS combination with
doxorubicin, as compared to 21.061.0 in the saline group (Fig. 5b).
It was also observed that the combined treatment of MBO-asGCS
with doxorubicin distinctly isolated tumor from around tissues, in
contrast to the other treatment groups (Fig. 5c). Three lung
metastases were found in the saline as well as in the MBO-SC
control groups (10 mice/group), but none in the MBO-asGCS
treatment groups. Further assessments showed that MBO-asGCS
specifically suppressed GCS expression in tumors (Fig. 6). MBO-
asGCS decreased GCS mRNA to approximately 30% (5,591 vs.
18,130 copies; 6,006 vs. 15,005 copies) in tumors, as compared
with saline or treatment with doxorubicin alone (Fig. 6a); however,
MBO-SC treatment did not significantly modulate GCS mRNA
levels in either the presence or absence of doxorubicin (Fig. 6a).
The effects of MBO-asGCS on GCS expression were further
confirmed by GCS protein changes detected using Western
blotting and immunostaining (Fig. 6b, 6c).
We characterized dynamic changes of tumor ceramides via an
LC/MS assay. We found that doxorubicin exposures for 24 hr
enhanced C18-ceramide accumulation more than 4-fold (2.4 vs.
0.67 fmole/nmole Pi) in MDR tumors treated with MBO-asGCS;
however, doxorubicin alone or combined with MBO-SC could not
significantly affect C18-ceramide levels in tumors (Fig. 7a).
Correspondingly, the combination of MBO-asGCS and doxoru-
bicin increased caspase 3/7 levels by 4-fold greater (130 vs. 31
RLU/mg protein) and significantly enhanced amounts of active
form of caspase-7 detected by Western blotting (Fig. 7b). This
MBO-asGCS combined treatment also substantially increased the
number of apoptotic cells in MDR tumors, as detected by a
TUNEL assay (Fig. 7c). By contrast, doxorubicin alone or a
Figure 7. MBO-asGCS leads to ceramide-induced apoptosis in vivo. Mice bearing NCI/ADR-RE tumors were treated with MBOs (1 mg/kg,
intratumoral), doxorubicin (Dox, 2 mg/kg, ip), or combinations for 3 days. a. Ceramide analysis. Lipids were extracted from tumors treated with MBOs
(1 mg/kg every 3 days, 3 times) and indicated periods of doxorubicin treatments (Dox). Endogenous C18-ceramide was normalized to phosphorus (Pi).
*, p,0.001 compared with combination of MBO-SC and doxorubicin. b. Caspase-3/7 assay. After combination treatments of MBOs and Dox, tumors
were resected 48 hr after Dox injection. Upper bar graph, Caspase-3/7 activities in tumors were measured by using caspase-3/7 assay as described in
Methods. RLU, relative luminescence units; *, p,0.001 compared with doxorubicin treatment. Lower panel, active form of caspase-7 was detected by
Western blot. c. Apoptosis. Successive sections of tumors after treatments were stained with H&E, or subjected to TUNEL assay. Apoptotic cells
(TUNEL
+) exhibit green fluorescence (x 200).
doi:10.1371/journal.pone.0006938.g007
GCS and Cancer Drug Resistance
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6938combination of doxorubicin with MBO-SC did not significantly
increase caspase 3/7 or apoptosis in MDR tumors.
We assessed the accumulations of Cy3-labeled MBO-asGCS
after intraperitoneal administration (1 mg/kg, sampling 7 hr post-
dose). As shown in Fig. 8a, we found that MDR tumors took up
approximately 0.8% of MBO-asGCS and that amount was greater
than these in other tissues (pancreas, small intestine, stomach,
large intestine, serum, lung, brain, heart), excepting liver and
kidneys that are the major organs for oligonucleotide degradation
(5.8% in liver, 0.99% in kidney). After 48 hr of treatments, we
examined caspase-executed apoptosis in tissues. There were no
significant changes in caspase activity or apoptotic cells in lungs,
heart and liver of mice treated with MBO-asGCS combined with
doxorubicin (Fig. 8b). There was a 2-fold increase in caspase-3/7
activity (p.0.05) and a 3% increase in apoptotic cells in the
kidneys of mice treated with MBO-asGCS and doxorubicin, as
compared with the saline control group; however, these increases
were no significant differences, as compared with doxorubicin
treatment groups (Fig. 8b).
Discussion
In the present study, we examine the effect of MBO against
GCS on cancer drug resistance. These results demonstrate, for the
first time, that suppressing GCS overexpression specifically
reverses drug resistance, and attenuates tumor progression.
Overexpressed GCS has been found in drug-resistant cancer
cells and in tumors [3,14–17,46,47]; however, whether ceramide
glycosylation by GCS constitutes a significant mechanism by
which tumors develop the resistance has been less studied. GCS
are overexpressed in MDR cancer cell lines of human breast
(MCF-7-P500), cervix (KB-A1), ovary (A2780-AD), colon
(SW620AD) and leukemia (K56/A02, HL-60/ADR) that have
been selected by anthracycline [14–17,48]. GCS overexpression
was also found in MDR murine EMT6/AR1 breast cancer cells in
this study (Fig. 2). In addition to GCS, overexpression of several
other genes including MDR1 and Bcl-2, and mutant tumor
suppressor p53 are known to cause these cells resistance, particular
sample as NCI/ADR-RE cells [3,14,31]. Efficient inhibition of
GCS in NCI/ADR-RE cells in vivo thus offered the opportunity to
prove and clarify GCS roles in cancer drug resistance. We
employed MBO as a specific tool in this study, since this second-
generation antisense oligonucleotide displays higher efficiency and
more stability than PS-oligo in vivo [27,49]. We found that MBO-
asGCS enhances doxorubicin sensitivity by 83-fold and 43-fold in
MDR NCI/ADR-RE and EMT6/AR1 cells, respectively, and by
220% in MDR tumor xenografts of NCI/ADR-RE. Given that
MBO-asGCS accumulates more in tumors (Fig. 8a) and equally in
both drug-resistant and -sensitive cells (Fig. 1a), it is reasonably
concluded that drug resistance of tumors, at least of some, depend
on GCS overexpression. Targeting GCS can eliminate tumors
with poor response to conventional chemotherapy, such as
doxorubicin. The suppression of GCS by MBO-asGCS restores
ceramide signaling (particular C18-ceramide) during the course of
doxorubicin treatment, thereby promoting caspase-executed
apoptotic death in cells and in tumors. These data demonstrate
that ceramide glycosylation by GCS plays a key role in MDR
tumor survival and growth, thus GCS is an important target for
improving cancer chemotherapy.
Previous studies have shown that several approaches inhibiting
GCS reverse drug resistance in cancer cells, however, a potential
therapeutic agent that efficiently inhibits GCS in vivo remains to be
developed. One of GCS inhibitors, PDMP overcomes drug
resistance in cell lines of breast, ovarian and colon cancer
[19,21,22,25]. However, like others, the specificity and efficiency
of PDMP is limited, as the active site and the catalytic mechanism
of GCS have not yet been well characterized [50–53]. Transfec-
tion of siRNA or antisense sequence (full length) has been found to
specifically silence the GCS gene and sensitize MDR cells to
several first-line anticancer drugs [3,20,26]. Inadequacy of delivery
and low levels of therapeutic gene expressed in vivo, which are
Figure 8. Accumulations and effects of MBO-asGCS in normal tissues. a. MBO-asGCS accumulations. After 7 hr injection of Cy3-labeled
MBO-asGCS (ip, 3 mice/each), tissues were removed and homogenized immediately. Fluorescence was measured and normalized against tissue
weight. b. Apoptosis analysis. Mice were treated with combination of MBOs (1 mg/kg every three days, ip, for three times) and Dox (2 mg/kg, ip, for
48 hr; 3 mice/group). Upper bar graph, Caspase-3/7 activities in heart, lung, liver and kidney were assessed by using caspase-3/7 assay. RLU, relative
luminescence units; *, p,0.05 compared with saline control. Lower panel, apoptotic cells in kidney were detected by using TUNEL staining.
doi:10.1371/journal.pone.0006938.g008
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antisense gene transfection in vivo studies. Our previous work
showed that PS-oligo specifically suppresses GCS expression and
efficiently reversed drug resistance in cells [15,23]. A MBO that is
modified by addition of several 29-O-methylribonucleotides in
DNA sequence has significantly improve the in-vivo stability,
binding affinity, and biodistribution of oligos [27,54,55]. Indeed,
we found that the new MBO-asGCS targeting human GCS
reported herein, efficiently suppressed GCS expression and
sensitized MDR tumor to doxorubicin in mice. More interestingly,
tracking Cy3-labeled MBO-asGCS in mice revealed that MDR
tumors took up 0.8% of administered MBO-asGCS; This tumor
uptake level is greater than in other normal tissues (pancreas, small
intestine, stomach, large intestine, serum, lung, brain, heart),
excepting liver and kidneys. Assessments of caspase-executed
apoptosis suggest that MBO-asGCS can significantly augment
doxorubicin cytotoxicity in MDR tumors (Fig. 7), but not in
kidney (Fig. 8). These results suggest that MBO-asGCS is an
efficient agent to suppress GCS overexpression specifically in
MDR tumors.
In conclusion, the present work primarily demonstrates that
GCS overexpressed in cancers, at least in metastatic breast cancer,
represents a viable and likely important target for the treatment of
drug-resistant cancers. MBO-asGCS constitutes a specific and
effective GCS inhibitor and appears to have great potential to be
developed to an antineoplastic agent.
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